With our extensive experience in lab based research, new therapy development and events, TRI is glad to extend our in-house expertise to new partners.
Data Sciences: our stats team recently arranged data from a registry of 57,000+ patients to underscore the development of a risk calculator to help clinicians decide on effective and safe courses of treatment for AF patients. The tool has seen excellent adoption globally via QxMD.
Comms and Events: TRI has independently organised the International Society of Thrombosis congress for 20+ years, including the development of research presentations as well as logistics and communications support.
